Women and adults aged 66 to 75 saw the most significant decrease in obesity.In Florida, a series of actions in 2024 chipped away the obesity rate: sales of weight-loss medications soared, new paths to getting the drugs opened, and the state-imposed prescribing requirements helped to ensure successful outcomes.There are currently three medications (GLP-1s) on the market that the FDA has specifically approved to treat obesity Wegovy, Zepbound, or Saxenda
Even injection users find tablets appealing More than two thirds ( 71.88% ) of previous GLP-1 injection users said a daily tablet feels more appealing than a weekly injection, while 66.67% of current injection users agreed, showing strong interest in oral options even among experienced users
According to the company's disclosures, the platform may provide access to FDA-approved semaglutide and tirzepatide medications manufactured by major pharmaceutical companies, depending on clinician evaluation and patient eligibility
The OASIS 4 clinical trial published in the New England Journal of Medicine in 2025 followed adults with overweight or obesity for 71 weeks
These medications mimic the GLP-1 hormone (and GIP in the case of Tirzepatide), which helps: Suppress appetite by acting on the brains hunger centers Improve insulin sensitivity to combat metabolic resistance Reduce inflammation , a key trigger in autoimmune flares Preserve lean muscle while promoting fat loss Stabilize blood sugar , reducing crashes that lead to fatigue and mood swings Why Its Especially Beneficial for Women with Hashimotos Weight Loss that Finally Works Women with Hashimotos often gain weight quickly and lose it slowly if at all
Gastrointestinal adverse events were the most common, and treatment discontinuations increased with higher doses, reinforcing the importance of careful patient selection and shared decision-making
